Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC

Lung cancer is the most common cause of cancer death worldwide1. Non-small cell lung carcinoma (NSCLC) accounts for around 85% of lung cancer cases. The standard treatment for patients with stage I and II NSCLC is surgery based, with or without postoperative chemotherapy depending on the pathological T and N status. Treatment for stage III NSCLC consists either of concurrent chemoradiation, or surgery with perioperative chemotherapy with or without thoracic radiotherapy2. After surgery, the 5-year survival rates range between 23 and 83%, depending on stage3.

Source: Lung Cancer - September 2, 2019 Category: Cancer & Oncology Authors: Taylor Leroy, Elisabeth Monnet, St éphane Guerzider, Pascale Jacoulet, Bernardino De Bari, Pierre-Emmanuel Falcoz, Marie Gainet-Brun, Jean Lahourcade, Faraj Alfreijat, Hamadi Almotlak, Olivier Adotevi, Didier Pernet, Jean-Charles Polio, Maxime Desmarets, Source Type: research